ARTICLE | Emerging Company Profile
Rectify: Restoring the function of ABC transporters
Leveraging experience from drugging CFTR at Vertex, Rectify’s team is developing precision therapies for other members of the transporter family
October 19, 2021 11:25 PM UTC
With $100 million in series A funding, Rectify is developing personalized therapies to restore ATP-binding cassette transporter function in multiple organs, with an initial focus on the liver.
The company debuted on Thursday with the financing, which was co-led by Atlas Venture, Omega Funds, Forbion and Longwood Fund...